BridgeBio Pharma Free Cash Flow 2018-2024 | BBIO

BridgeBio Pharma free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • BridgeBio Pharma annual free cash flow for 2023 was $-0.529B, a 24.68% increase from 2022.
  • BridgeBio Pharma annual free cash flow for 2022 was $-0.424B, a 16.99% decline from 2021.
  • BridgeBio Pharma annual free cash flow for 2021 was $-0.511B, a 25.53% increase from 2020.

BridgeBio Pharma Free Cash Flow 2018-2024 | BBIO

  • BridgeBio Pharma annual free cash flow for 2023 was $-0.529B, a 24.68% increase from 2022.
  • BridgeBio Pharma annual free cash flow for 2022 was $-0.424B, a 16.99% decline from 2021.
  • BridgeBio Pharma annual free cash flow for 2021 was $-0.511B, a 25.53% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$21B
Dr Reddy's Laboratories (RDY)$11.3B
Bausch Health Cos (BHC)$2.7B
Supernus Pharmaceuticals (SUPN)$2.2B
Amphastar Pharmaceuticals (AMPH)$1.8B
Personalis (PSNL)$354M
Taysha Gene Therapies (TSHA)$307M
Assembly Biosciences (ASMB)$88M
Sol-Gel Technologies (SLGL)$23M
Evoke Pharma (EVOK)$7M
Teligent (TLGT)$0M